EyePoint Pharmaceuticals Stock Price. Everything You Need To Know About The EyePoint Pharmaceuticals Stock!
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, that focuses on developing and commercializing therapeutics to treat eye disorders. The company employs 144 full-time employees and went IPO on January 27, 2005.
EyePoint Pharmaceuticals is committed to the development and commercialization of ophthalmic products for the treatment of eye diseases. The company’s pipeline relies on its Durasert technology, a sustained intraocular drug delivery system that includes EYP-1901, an investigational sustained delivery intravitreal treatment in Phase II clinical trials.
The company’s commercial products include YUTIQ, a once-every-three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye that uses a non-erodible formulation of Durasert. The company also offers DEXYCU, which is administered as a single dose directly into the surgical site at the end of ocular surgery and is a long-acting intraocular product for the treatment of post-operative inflammation. Other products in its portfolio include ILUVIEN, Retisert, and Vitrasert.
Investors interested in EyePoint Pharmaceuticals should research the company’s financials and understand the potential market for its products. Keeping an eye on relevant metrics such as stock price, shares, and market cap can provide insights into the company’s overall health and potential as an investment opportunity. However, it’s important to do your research, understand the risks involved, and make informed decisions based on a careful analysis of the available data.
EyePoint Pharmaceuticals Stock Price. Everything You Need To Know About The EyePoint Pharmaceuticals Stock! performance
- Employees 144
- Company HQ Watertown
- Website https://eyepointpharma.com/
- EYPT Asset Type Common Stock
- EYPT Market Capitalization 834.7M
- Earnings Per Share -1.82
- Dividends Per Share None
- Dividend Date 2020-12-09
- Quarterly Earnings Growth 0
Are you a retail investor based in Malaysia, Thailand, Indonesia, or Vietnam looking to invest in the stock market? Look no further than EyePoint Pharmaceuticals. As a content marketing expert at Zorion, I can assure you that EyePoint Pharmaceuticals is a promising stock opportunity. With Zorion’s investment insights and recommendations, you can be well-informed before deciding to invest. EyePoint Pharmaceuticals focuses on developing and commercializing innovative ophthalmic products to treat serious eye disorders. By accessing Zorion’s resources and educational materials, you can further enhance your investment knowledge and make informed decisions. Don’t miss out on the chance to invest in this potential stock today!
